Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma

Md Sazzad Hassan, Niranjan Awasthi, Jun Li, Fiona Williams, Margaret Schwarz, Roderich E. Schwarz, Urs von Holzen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

Original languageEnglish (US)
Pages (from-to)426-435
Number of pages10
JournalTranslational Oncology
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Paclitaxel
Nanoparticles
Adenocarcinoma
Therapeutics
Survival
Stathmin
Western World
Spindle Apparatus
Carboplatin
Albumin-Bound Paclitaxel
cremophor
Heterografts
Albumins
Survival Rate
Cell Proliferation
Apoptosis
Water
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. / Hassan, Md Sazzad; Awasthi, Niranjan; Li, Jun; Williams, Fiona; Schwarz, Margaret; Schwarz, Roderich E.; von Holzen, Urs.

In: Translational Oncology, Vol. 11, No. 2, 01.04.2018, p. 426-435.

Research output: Contribution to journalArticle

Hassan, Md Sazzad ; Awasthi, Niranjan ; Li, Jun ; Williams, Fiona ; Schwarz, Margaret ; Schwarz, Roderich E. ; von Holzen, Urs. / Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. In: Translational Oncology. 2018 ; Vol. 11, No. 2. pp. 426-435.
@article{3bf0b55b54c447aeb621b64ffc4ea350,
title = "Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma",
abstract = "Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20{\%}. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.",
author = "Hassan, {Md Sazzad} and Niranjan Awasthi and Jun Li and Fiona Williams and Margaret Schwarz and Schwarz, {Roderich E.} and {von Holzen}, Urs",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2018.01.022",
language = "English (US)",
volume = "11",
pages = "426--435",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma

AU - Hassan, Md Sazzad

AU - Awasthi, Niranjan

AU - Li, Jun

AU - Williams, Fiona

AU - Schwarz, Margaret

AU - Schwarz, Roderich E.

AU - von Holzen, Urs

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

AB - Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel albumin-stabilized, cremophor-free and water soluble nanoparticle formulation of paclitaxel, and the potential role of nab-paclitaxel has not been tested yet in experimental EAC. Here we tested the antiproliferative and antitumor efficacy with survival advantage of nab-paclitaxel as monotherapy and in combinations in in-vitro, and in murine subcutaneous xenograft and peritoneal metastatic survival models of human EAC. Nab-paclitaxel significantly inhibited in-vitro cell proliferation with higher in-vivo antitumour efficacy and survival benefit compared to paclitaxel or carboplatin treatments both in mono- and combination therapies. Nab-paclitaxel treatment increased expression of mitotic-spindle associated phospho-stathmin, decreased expression of proliferative markers and enhanced apoptosis. This study demonstrates that nab-paclitaxel had stronger antiproliferative and antitumor activity in experimental EAC than the current standard chemotherapeutic agents which supports the rationale for its clinical use in EAC.

UR - http://www.scopus.com/inward/record.url?scp=85044749524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044749524&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2018.01.022

DO - 10.1016/j.tranon.2018.01.022

M3 - Article

AN - SCOPUS:85044749524

VL - 11

SP - 426

EP - 435

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -